9926 Community Narratives

AnalystConsensusTarget's

Fair Value

Fair Value HK$158.28 37.3% undervalued

9926: Positive Late-Stage Trial Results Will Drive New Market Opportunities

AnalystHighTarget's

Fair Value

Fair Value HK$224.06 55.7% undervalued

Breakthrough Immunotherapies And Aging Trends Will Revitalize Global Oncology

AnalystLowTarget's

Fair Value

Fair Value HK$125.02 20.6% undervalued

Aggressive Pricing In China Will Compress Margins Despite Clinical Promise

About 9926

Founded: 2012
Employees: 4082
CEO: Yu Xia
WebsiteView website: www.akesobio.com

Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, and recurrent or refractory classical Hodgkin lymphoma; AK109, a PD-1 monoclonal antibody to treat G/GEJ patients; penpulimab, a PD-1 for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC); and tagitanlimab, a PD-L1 for treating recurrent or metastatic NPC. In addition, the company develops AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia and mixed hyperlipidemia; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis. Further, its preclinical product includes AK120 to treat moderate-to-severe atopic dermatitis. The company was founded in 2012 and is headquartered in Zhongshan, the People’s Republic of China.

Recent 9926 News & Updates

Announcement • Sep 17

Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Receives NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate

Akeso, Inc. announced that AK158D1, its investigational next-generation bispecific antibody-drug conjugate (ADC) targeting EGFR and TROP2, has secured Phase I clinical trial clearance from the Center for Drug Evaluation (CDE) under China's National Medical Products Administration (NMPA). The trial will assess the candidate in patients with advanced malignant solid tumors.AK158D1 is Akeso's fourth ADC to enter clinical development and joins the Company's growing clinical-stage ADC portfolio, which includes AK146D1 (TROP2/Nectin-4), AK138D1 (HER3), and AK157D1 (B7-H3). It is also Akeso's second bispecific ADC to reach the clinic, further advancing the Company's global strategy of combining next-generation immuno-oncology (IO2.0) approaches with next-generation ADC platforms (ADC2.0).EGFR (epidermal growth factor receptor) and TROP2 (trophoblast cell surface antigen 2) constitute a highly promising target pair for bispecific ADC therapeutic development, with broad co-expression across a spectrum of solid tumor types. Each target has well-validated anti-tumor mechanisms of action, and their dual targeting holds significant synergistic anti-tumor potential. To date, single-target ADCs directed against either EGFR or TROP2 have been constrained by three key clinical limitations: narrow tumor coverage, off-target toxicity, and multidrug resistance. As a next-generation dual-targeting ADC, AK158D1 integrates the precise tumor recognition enabled by bispecific antibodies, a highly potent cytotoxic payload, and an enhanced safety profile to create a potential breakthrough ADC to address the shortcomings of conventional single-target ADC modalities. Preclinical data for AK158D1 have demonstrated potent anti-tumor activity with a favorable safety profile, supporting its potential as a novel therapeutic option for a wide range of patients, including those who are refractory to, intolerant, or ineligible for existing standard of care regimens. Akeso is advancing its IO2.0 + ADC2.0 strategy, built on proprietary bispecific and multi-specific antibody technology and centered on cornerstone IO2.0 assets including ivonescimab and cadonilimab. Through this approach, the Company is elevating treatment standards for major diseases worldwide and building a broad oncology portfolio to create next-generation standard of care. Leveraging its technological leadership in bispecific and multi-specific antibodies, Akeso is systematically building a comprehensive global IO2.0 + ADC2.0 therapeutic matrix for major diseases worldwide. In the immuno-oncology field, Akeso has two approved bispecific antibodies for cancer treatment. The Company is actively evaluating ivonescimab and cadonilimab in combination with its proprietary next-generation ADC candidates. Increasingly, global partners recognize both ivonescimab and cadonilimab as preferred agents for combination regimens and breakthrough therapy explorations across a wide spectrum of tumor types. In the ADC space, Akeso has built a pipeline of highly differentiated next-generation candidates, including AK146D1, AK138D1, AK157D1 and AK158D1, which are already in clinical development. These agents are designed to address the narrow therapeutic window and safety limitations commonly associated with first-generation ADCs.

Recent updates

No updates

Akeso, Inc. Stock Price

9926 Share Price Performance

9926 Community Narratives

9926: Positive Late-Stage Trial Results Will Drive New Market Opportunities

Breakthrough Immunotherapies And Aging Trends Will Revitalize Global Oncology

Aggressive Pricing In China Will Compress Margins Despite Clinical Promise

Aggressive Pricing In China Will Compress Margins Despite Clinical Promise

9926: Positive Late-Stage Trial Results Will Drive New Market Opportunities

Breakthrough Immunotherapies And Aging Trends Will Revitalize Global Oncology

Trending Discussion

Recently Updated Narratives

9926: Lung Cancer Survival Data Will Drive Further Upside Potential

9926: New Cancer Approvals And ADC Pipeline Will Support Future Oncology Upside

9926: Expanding Oncology Pipeline And Trial Progress Will Support Long Term Upside

Snowflake Analysis

Akeso, Inc. Key Details

About 9926

Recent 9926 News & Updates

Akeso Gains NMPA Clearance to Begin Phase I Trial of Bispecific ADC AK158D1

Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Receives NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate

9926: Lung Cancer Survival Data Will Drive Further Upside Potential

Recent updates

Akeso, Inc. Competitors

Hansoh Pharmaceutical Group

WuXi Biologics (Cayman)

Innovent Biologics

Sichuan Kelun-Biotech Biopharmaceutical